News Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen After winding up its stem cell therapy operations last month, Vor Bio has reinvented itself as an autoimmune disease-focused biotech.
News EU kicks off review of GSK's linerixibat in PBC GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.
News Data at EULAR back Biogen, UCB's first-in-class lupus drug Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.
News FDA fast-tracks Teva's coeliac disease treatment Teva gets fast-track status from the FDA for a coeliac disease drug with a mechanism that has proved tough to crack.
News Manufacturing issues scupper Savara's lead drug filing Savara shares are pummelled after the FDA says it cannot accept a filing for lead drug Molbreevi, but it is still hopeful of an approval in 2026.
News Sanofi signs $1.9bn deal to buy Dren Bio autoimmune drug Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.
News ACIP backs block on flu vaccines with thimerosal additive The new CDC vaccines committee has voted against the use of thimerosal, a preservative that anti-vaccine activists have linked to autism.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face